Alkylating agents in bronchogenic carcinoma

Green, Robert A.; Humphrey, Edward W.; Close, H.G.; Patno, Mary Ellen

doi:10.1016/0002-9343(69)90071-0

Cited by 317 publications

(49 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a landmark study, the VALSG demonstrated that chemotherapy in the form of three courses of cyclophosphamide improved survival when compared to best supportive care in ED-SCLC [13]. The superiority of etoposide and cisplatin (EP) as treatment for ED-SCLC was first introduced in the 1980s through a series of uncontrolled trials that demonstrated that EP could increase response rates in the first-line setting and salvage patients who had failed alkylating-based therapy [14].…”

Section: Ed-sclcmentioning

confidence: 99%

Small Cell Lung Cancer: Past, Present, and Future

Rodriguez

Lilenbaum

2010

Curr Oncol Rep

View full text Add to dashboard Cite

Small cell lung cancer (SCLC) accounts for about 10% to 15% of all lung cancers. It is characterized by its rapid doubling time, high rate of dissemination, and increased sensitivity to chemotherapy and radiation. Although the incidence of SCLC has been steadily decreasing over time, it remains a serious public health problem given its aggressive clinical behavior and the lack of effective therapies. This review looks at the evolution of SCLC treatment and the standard treatments that are currently available, including platinum-based combination chemotherapy, hyperfractionated thoracic radiation, and prophylactic cranial irradiation. The development of novel therapies for SCLC has been lagging behind, but completed clinical trials and ongoing investigations are helping us define what will be the best therapeutic targets for this disease.

show abstract

Section: Ed-sclcmentioning

confidence: 99%

Small Cell Lung Cancer: Past, Present, and Future

Rodriguez

Lilenbaum

2010

Curr Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Other factors, such as the histological SCLC subtype, are linked to a worse prognosis with early dissemination, but on the other hand, are associated with greater chemo-sensitivity than NSCLC [3].…”

Section: Introductionmentioning

confidence: 99%

Gender-Related Survival in Different Stages of Lung Cancer—A Population Study over 20 Years

Svensson¹,

Ewers²,

Ohlsson³

et al. 2014

OJIM

View full text Add to dashboard Cite

Introduction: Tumour stage is the most important prognostic factor in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The aim of this study was to evaluate if female gender was a prognostic factor in different tumour stages in relation to histology and given therapy. Methods: From 1989-2008, 1497 patients in eastern Scania, in southern Sweden with 202,000 inhabitants, were referred and prospectively registered. Tumour stage, performance status, lung cancer type and primary therapy were registered. Results: In NSCLC, female patients in stages 1 and 2 who were treated with surgery had a better 5-year survival rate (79.4%), compared to males (60.6%; p = 0.0004). Female patients in stage 3 with active therapy (surgery and/or radiotherapy and/or chemotherapy) had a better 5-year survival than males (20.6% vs. 10.5%, respectively, p = 0.0006). Female patients with adenocarcinoma were favourable in stages 1-3. In stage 4, there was no survival difference between females and males. In SCLC, females with limited disease (LD) and active therapy (chemotherapy ± radiotherapy ± surgery) had a higher 5-year survival rate (28%) than males (5.6%); p = 0.001. Females with extensive disease (ED) and active therapy (chemotherapy ± radiotherapy) had a better 5-year survival (3.9%) compared to males (0.7%); p = 0.023. In multivariate analyses, patient performance status at diagnosis was also an independent prognostic factor in all tumour stages of lung cancer. Conclusions: This population-based study corroborates a female survival advantage in NSCLC stages 1-3, but not in metastatic stage 4, and this is also demonstrated for the adenocarcinoma subgroup. The study also confirms better prognosis in females with SCLC in both LD and ED. The study also demonstrates the importance of patient performance status as a prognostic factor in all stages of lung cancer.

show abstract

“…They are highly malignant tumors with a median survival of about 2 months when diagnosed with extrathoracic disease9. 18 and with a 5-year survival of less than 1yo. 22 On roentgenogram of the chest, a hilar or perihilar mass or a hilar prominence is the most common finding, occuring in about 750/, of patients examined.?…”

mentioning

confidence: 94%